WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2010151216) METHOD FOR TREATING A PATIENT AT RISK FOR DEVELOPING AN NSAID-ASSOCIATED ULCER
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2010/151216    International Application No.:    PCT/SE2010/050712
Publication Date: 29.12.2010 International Filing Date: 23.06.2010
IPC:
A61K 31/4439 (2006.01), A61K 9/24 (2006.01), A61P 19/02 (2006.01), A61P 29/00 (2006.01)
Applicants: ASTRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE) (For All Designated States Except US).
POZEN Inc. [US/US]; 1414 Raleigh Road Chapel Hill, NC 27517 (US) (For All Designated States Except US).
AULT, Brian [US/US]; (US) (For US Only).
HWANG, Clara [US/US]; (US) (For US Only).
ORLEMANS, Everardus [NL/US]; (US) (For US Only).
PLACHETKA, John R. [US/US]; (US) (For US Only).
SOSTEK, Mark [US/US]; (US) (For US Only)
Inventors: AULT, Brian; (US).
HWANG, Clara; (US).
ORLEMANS, Everardus; (US).
PLACHETKA, John R.; (US).
SOSTEK, Mark; (US)
Agent: ASTRAZENECA INTELLECTUAL PROPERTY; AstraZeneca AB S-151 85 Södertälje (SE)
Priority Data:
61/220,420 25.06.2009 US
61/225,970 16.07.2009 US
61/310,525 04.03.2010 US
Title (EN) METHOD FOR TREATING A PATIENT AT RISK FOR DEVELOPING AN NSAID-ASSOCIATED ULCER
(FR) PROCEDE POUR LE TRAITEMENT D'UN PATIENT A RISQUE DE DEVELOPER UN ULCERE ASSOCIE A NSAID
Abstract: front page image
(EN)The present disclosure is directed to a method for treating a disease or disorder in a patient at risk of developing an NSAID-associated ulcer by administering a pharmaceutical composition in unit dose form comprising naproxen, or pharmaceutically acceptable salt thereof, and esomeprazole, or pharmaceutically acceptable salt thereof. The unit dose is designed to release at least a part of the esomeprazole independent of pH (e.g. at a pH of 0 or more) whereas the naproxen is not released until the pH or the surrounding medium is 3.5 or higher.
(FR)La présente invention concerne un procédé pour le traitement d'une maladie ou d'un trouble chez un patient à risque de développer un ulcère associé à NSAID par l'administration d'une composition pharmaceutique sous forme de dose unitaire comprenant du naproxène, ou un sel pharmaceutiquement acceptable de celui-ci, et de l'ésoméprazole, ou un sel pharmaceutiquement acceptable de celui-ci. La dose unitaire est destinée à libérer au moins une partie de l'ésoméprazole indépendamment de pH (par exemple, à un pH égal ou supérieur à 0) tandis que le naproxène n'est libéré que lorsque le pH ou le milieu environnant est égal ou supérieur à 3,5.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)